Literature DB >> 10508035

Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada.

A C Labbé1, A M Bourgault, J Vincelette, P L Turgeon, F Lamothe.   

Abstract

The objective of the present study was to analyze the susceptibility profiles of 911 clinical strains of the Bacteroides fragilis group isolated from 1992 to 1997 in our institution in order to monitor susceptibility changes over time. Whereas the rates of resistance to metronidazole, imipenem, piperacillin-tazobactam, ticarcillin-clavulanic acid, penicillin, piperacillin, and cefoxitin remained essentially unchanged, there was a significant increase in the rates of resistance to clindamycin, which rose from 8.2% in 1992 to 19.7% in 1997 (P < 0.0004).

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10508035      PMCID： PMC89511          DOI： 10.1128/AAC.43.10.2517

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

Review 1.  Present studies of therapy for anaerobic infections.

Authors:  S M Finegold; H M Wexler
Journal:  Clin Infect Dis       Date:  1996-12       Impact factor: 9.079

2.  Trends in antimicrobial resistance of the Bacteroides fragilis group: a 20-year study at a medical center in Buenos Aires, Argentina.

Authors:  H Bianchini; L B Fernández Canigia; C Bantar; J Smayevsky
Journal:  Clin Infect Dis       Date:  1997-09       Impact factor: 9.079

3.  Clindamycin resistance in the Bacteroides fragilis group: association with hospital-acquired infections.

Authors:  D Dalmau; M Cayouette; F Lamothe; J Vincelette; N Lachance; A M Bourgault; C Gaudreau; P L Turgeon
Journal:  Clin Infect Dis       Date:  1997-05       Impact factor: 9.079

Review 4.  Antimicrobial resistance in anaerobes.

Authors:  B A Rasmussen; K Bush; F P Tally
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

5.  Survey of Bacteroides fragilis group susceptibility patterns in Canada.

Authors:  A M Bourgault; F Lamothe; D J Hoban; M T Dalton; P C Kibsey; G Harding; J A Smith; D E Low; H Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

6.  Emerging resistance of anaerobic bacteria to antimicrobial agents in South Korea.

Authors:  K Lee; Y Chong; S H Jeong; X S Xu; O H Kwon
Journal:  Clin Infect Dis       Date:  1996-12       Impact factor: 9.079

7.  Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroides fragilis group species from 1990 to 1994.

Authors:  D R Snydman; L McDermott; G J Cuchural; D W Hecht; P B Iannini; L J Harrell; S G Jenkins; J P O'Keefe; C L Pierson; J D Rihs; V L Yu; S M Finegold; S L Gorbach
Journal:  Clin Infect Dis       Date:  1996-12       Impact factor: 9.079

8.  Survey of anaerobic susceptibility patterns in Canada.

Authors:  A M Bourgault; G K Harding; J A Smith; G B Horsman; T J Marrie; F Lamothe
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

9.  Longitudinal study of susceptibilities of species of the Bacteroides fragilis group to five antimicrobial agents in three medical centers.

Authors:  P Turgeon; V Turgeon; M Gourdeau; J Dubois; F Lamothe
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

10.  Evolution of antimicrobial susceptibility in isolates of the Bacteroides fragilis group in Spain.

Authors:  J E García-Rodríguez; J E García-Sánchez
Journal:  Rev Infect Dis       Date:  1990 Jan-Feb
  10 in total
  8 in total

1.  Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.

Authors:  K E Aldridge; D Ashcraft; K Cambre; C L Pierson; S G Jenkins; J E Rosenblatt
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

2.  In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains.

Authors:  C Betriu; A Sánchez; M L Palau; M Gómez; J J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

3.  Bacteroides fragilis group: trends in resistance.

Authors:  Manfred Fille; Monica Mango; Matthias Lechner; Reiner Schaumann
Journal:  Curr Microbiol       Date:  2006-01-31       Impact factor: 2.188

4.  In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain.

Authors:  Carmen Betriu; Iciar Rodríguez-Avial; Blas Ali Sánchez; María Gómez; Juan Alvarez; Juan J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

5.  Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates.

Authors:  David W Hecht; J R Osmolski
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

6.  Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.

Authors:  Chia-Ying Liu; Yu-Tsung Huang; Chun-Hsing Liao; Li-Ching Yen; Hsiu-Ying Lin; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

7.  High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan.

Authors:  Lee-Jene Teng; Po-Ren Hsueh; Jui-Chang Tsai; Shwu-Jen Liaw; Shen-Wu Ho; Kwen-Tay Luh
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

8.  Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline.

Authors:  Wanda C Reygaert
Journal:  Ther Clin Risk Manag       Date:  2010-09-07       Impact factor: 2.423
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.